SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-21-025271
Filing Date
2021-10-13
Accepted
2021-10-13 08:35:27
Documents
14
Period of Report
2021-10-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37905
2 ex99-1.htm EX-99.1 15388
3 ex99-1_001.jpg GRAPHIC 3514
  Complete submission text file 0001493152-21-025271.txt   233563

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE prph-20211013.xsd EX-101.SCH 3036
5 XBRL LABEL FILE prph-20211013_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE prph-20211013_pre.xml EX-101.PRE 22366
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3484
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 211320217
SIC: 2834 Pharmaceutical Preparations